Smoothened蛋白抑制剂的研究进展  

Research Progress of Smoothened Inhibitors

作　　者：赵明明[1] 李颖[1] 刘建宇[1] ZHAO Ming-ming;LI Ying;LIU Jian-yu(School of Pharmaceutical Engineering,Shenyang Pharmaceutical University,Liaoning Shenyang 110016,China)

机构地区：[1]沈阳药科大学制药工程学院,辽宁沈阳110016

出　　处：《辽宁化工》2018年第9期969-972,977,共5页Liaoning Chemical Industry

基　　金：辽宁省教育厅科学研究一般项目;项目号:L2015532

摘　　要：Smoothened(SMO)蛋白是Hedgehog(Hh)信号通路中的关键受体,通过对SMO蛋白的抑制能够防止Gli转录因子激活下游信号通路,从而抑制癌症的发生与发展。对SMO蛋白抑制剂的研究已经成为Hh信号通路的研究热点。本文综述了国内外已经上市的,正在进行临床实验以及正在研发的SMO蛋白抑制剂。Smoothened （SMO） protein is a key receptor in Hedgehog （Hh） signaling pathway. The transcription factor Gli can prevent downstream signaling pathway from being activated by inhibiting SMO protein. The Smoothened inhibitors can inhibit the occurrence and development of cancer. Research on SMO protein inhibitors has become a research hotspot of Hh signaling pathway. In this paper, research progress of SMO protein inhibitors was reviewed.

关 键 词：HEDGEHOG信号通路 Smoothened蛋白抑制剂 肿瘤 

分 类 号：R914[医药卫生—药物化学]